{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=25",
    "query": {
      "intervention": "Control/Placebo group",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 5231,
    "total_pages": 524,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control%2FPlacebo+group&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T13:59:53.565Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05158387",
      "title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Tozorakimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 1172,
      "start_date": "2022-02-07",
      "completion_date": "2026-03-22",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 34,
      "location_summary": "Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05158387"
    },
    {
      "nct_id": "NCT01000493",
      "title": "Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "orvepitant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 132,
      "start_date": "2009-11-02",
      "completion_date": "2010-06-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000493"
    },
    {
      "nct_id": "NCT06724614",
      "title": "Efficacy and Safety of VDPHL01 in Males With AGA",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Androgenetic Alopecia",
        "AGA",
        "Male Pattern Baldness"
      ],
      "interventions": [
        {
          "name": "VDPHL01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veradermics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 480,
      "start_date": "2024-11-06",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06724614"
    },
    {
      "nct_id": "NCT03818321",
      "title": "Urinary Track Infection Prevention After Urogynecological Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Tract Infections",
        "Urinary Retention Postoperative",
        "Pelvic Organ Prolapse"
      ],
      "interventions": [
        {
          "name": "Methenamine Hippurate 1 g tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TriHealth Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 185,
      "start_date": "2019-06-17",
      "completion_date": "2021-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818321"
    },
    {
      "nct_id": "NCT01483898",
      "title": "An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Ixmyelocel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vericel Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "35 Years to 90 Years"
      },
      "enrollment_count": 41,
      "start_date": "2012-02",
      "completion_date": "2014-03-25",
      "has_results": false,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483898"
    },
    {
      "nct_id": "NCT00484198",
      "title": "Study of Rivoglitazone in Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rivoglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1912,
      "start_date": "2007-04-23",
      "completion_date": "2009-02-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-27",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 70,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00484198"
    },
    {
      "nct_id": "NCT01129414",
      "title": "Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2009-06",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2011-12-15",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129414"
    },
    {
      "nct_id": "NCT02175121",
      "title": "Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-06291874",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 172,
      "start_date": "2014-08",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-15",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 19,
      "location_summary": "Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175121"
    },
    {
      "nct_id": "NCT00042406",
      "title": "Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Humax-CD4",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2002-03-04",
      "completion_date": "2003-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-28",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 50,
      "location_summary": "Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042406"
    },
    {
      "nct_id": "NCT02651584",
      "title": "Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use Disorders"
      ],
      "interventions": [
        {
          "name": "CAM2038 SC injection",
          "type": "DRUG"
        },
        {
          "name": "SL BPN/NX tabs",
          "type": "DRUG"
        },
        {
          "name": "placebo SC injections",
          "type": "DRUG"
        },
        {
          "name": "SL placebo tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braeburn Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 428,
      "start_date": "2015-12",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-08-22",
      "last_synced_at": "2026-11-11T13:59:53.565Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Hamilton",
          "state": "Alabama"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651584"
    }
  ]
}